Sagimet Biosciences Presents FASCINATE-2 Trial Data at Keystone Symposium
Event summary
- Sagimet Biosciences will present Phase 2b FASCINATE-2 trial data on denifanstat for MASH at the Keystone Symposium on April 13 and 15, 2026.
- Poster and oral presentations highlight correlation between reduced bile acids and histological improvements in MASH patients.
- Sagimet granted 9,600 stock options to a newly hired employee under Nasdaq Rule 5635(c)(4).
- Denifanstat met all primary endpoints in Phase 2b FASCINATE-2 trial and is being developed for MASH cirrhosis in combination with resmetirom.
The big picture
Sagimet's presentation of FASCINATE-2 data underscores the potential of denifanstat in addressing the unmet needs of MASH patients, particularly those with advanced fibrosis. The focus on bile acid reduction as a biomarker aligns with broader industry trends in precision medicine and metabolic disease treatment. The inducement grant reflects Sagimet's efforts to strengthen its leadership team amid critical clinical milestones.
What we're watching
- Biomarker Validation
- Whether reduced bile acid levels can serve as a reliable response biomarker for denifanstat treatment.
- Clinical Development
- The pace at which Sagimet advances denifanstat into Phase 3 trials for MASH cirrhosis.
- Strategic Partnerships
- How the collaboration with Ascletis in China impacts global development timelines.